Mawas Fatme, Peyre Marisa, Beignon Anne-Sophie, Frost Laura, Del Giudice Giuseppe, Rappuoli Rino, Muller Sylviane, Sesardic Dorothea, Partidos Charalambos D
Division of Bacteriology, National Institute for Biological Standards and Control, Hertfordshire, United Kingdom.
J Infect Dis. 2004 Sep 15;190(6):1177-82. doi: 10.1086/423327. Epub 2004 Aug 11.
We examined the antibody responses elicited in rats after transcutaneous immunization (TCI) with the Haemophilus influenzae type b (Hib)-cross-reacting material (CRM(197)) glycoconjugate vaccine coadministered with cholera toxin or mutants of heat-labile enterotoxin of Escherichia coli (LTK63 and LTR72) as adjuvants. The glycoconjugate vaccine was immunogenic, eliciting high antibody responses to the capsular polysaccharide of Hib and to diphtheria toxin. Passively transferred immune serum protected infant rats against challenge with the Hib Eagan strain and exhibited strong neutralizing activity against diphtheria toxin both in vitro and in vivo. The finding that TCI of rats can elicit antibody responses surpassing the minimum levels required for protective immunity against Hib and diphtheria suggests that this immunization strategy holds a lot of promise for future pediatric use. However, further studies are required to confirm the potential of TCI with glycoconjugate vaccines in humans.
我们研究了用b型流感嗜血杆菌（Hib）交叉反应物质（CRM(197)）糖共轭疫苗经皮免疫（TCI）大鼠后引发的抗体反应，该疫苗与霍乱毒素或大肠杆菌不耐热肠毒素突变体（LTK63和LTR72）作为佐剂共同给药。糖共轭疫苗具有免疫原性，能引发针对Hib荚膜多糖和白喉毒素的高抗体反应。被动转移的免疫血清可保护幼鼠免受Hib伊根菌株的攻击，并在体外和体内均表现出对白喉毒素的强中和活性。大鼠经皮免疫能引发超过针对Hib和白喉保护性免疫所需最低水平的抗体反应，这一发现表明这种免疫策略在未来儿科应用中有很大前景。然而，需要进一步研究来证实糖共轭疫苗经皮免疫在人类中的潜力。
